Publications by authors named "Carol Addy"

Claim this Profile
E
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kris V Kowdley, Christopher L Bowlus, Cynthia Levy, Ulus S Akarca, Mario Reis Alvares-da-Silva, Carol Addy

N Engl J Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Open Label, Randomized, Multicenter Study of Elafibranor in Children With Nonalcoholic Steatohepatitis.
Nidhi P Goyal, Ali Mencin, Kimberly P Newton, Janis Durelle, Carissa Carrier, Carol Addy

J Pediatr Gastroenterol Nutr· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Wage Workers and Health Benefits Use: Are We Missing an Opportunity?
Bruce W Sherman, Carol Addy

Popul Health Manag· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High intensity lifestyle intervention and long-term impact on weight and clinical outcomes.
Linda Gotthelf, Ya-Ting Chen, Srinivasan Rajagopalan, Elise Chi-Tao Wu, Ishita Doshi, Carol Addy

PLoS One· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Value-based health insurance design: how much does socioeconomic status matter?
Bruce W Sherman, Carol Addy

Am J Manag Care· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Wage With Employee Participation in Health Assessments and Biometric Screening.
Bruce W Sherman, Carol Addy

Am J Health Promot· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
Chai-Wan Kim, Carol Addy, Jun Kusunoki, Norma N Anderson, Stanislaw Deja

Cell Metab· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
Chai-Wan Kim, Carol Addy, Jun Kusunoki, Norma N Anderson, Stanislaw Deja

Cell Metab· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health Care Use And Spending Patterns Vary By Wage Level In Employer-Sponsored Plans.
Bruce W Sherman, Teresa B Gibson, Wendy D Lynch, Carol Addy

Health Aff (Millwood)· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
Saori Tsuchiya, Evan Friedman, Carol Addy, Akira Wakana, Daniel Tatosian

J Diabetes Investig· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.
Rajesh Krishna, Carol Addy, Daniel Tatosian, Xiaoli S Glasgow, Isaias Noel Gendrano Iii

J Clin Pharmacol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rethinking the Uses and Value of Employer-Sponsored Biometric Screening.
Bruce W Sherman, Carol Addy

J Occup Environ Med· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Age, Sex, and Obesity on the Single-Dose Pharmacokinetics of Omarigliptin in Healthy Subjects.
Carol Addy, Daniel A Tatosian, Xiaoli S Glasgow, Isaias Noel Gendrano, Christine McCrary Sisk

Clin Pharmacol Drug Dev· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lost in translation: healthcare utilization by low-income workers receiving employer-sponsored health insurance.
Bruce W Sherman, Wendy D Lynch, Carol Addy

Am J Manag Care· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Carol Addy, Daniel Tatosian, Xiaoli S Glasgow, Isaias N Gendrano, Eunkyung Kauh

Clin Ther· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving engagement in employer-sponsored weight management programs.
Bruce W Sherman, Carol Addy

Am J Manag Care· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergy at work: evidence development and assessment of the business value of investments in workforce health.
Bruce W Sherman, Carol Addy

Popul Health Manag· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users.
Kerri A Schoedel, Carol Addy, Bijan Chakraborty, Kim Rosko, Stephanie Dunbar

J Clin Psychopharmacol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist.
Xiujiang Susie Li, Jace Nielsen, Brenda Cirincione, Hankun Li, Carol Addy

AAPS J· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans.
Bindhu Karanam, Carol Addy, Thomas Bateman, Vijay Bhasker Reddy, Susie Li

Xenobiotica· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist.
Carol Addy, Patricia Jumes, Kimberly Rosko, Susie Li, Hankun Li

J Clin Pharmacol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
Carol Addy, Chris Assaid, David Hreniuk, Mark Stroh, Yang Xu

J Clin Pharmacol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse event.
Mark Stroh, Carol Addy, Yunhui Wu, S Aubrey Stoch, Nazaneen Pourkavoos

AAPS J· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
Jules I Schwartz, Stephanie Dunbar, Jinyu Yuan, Susie Li, Adrianna Gipson, Carol Addy

Adv Ther· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
Carol Addy, Paul Rothenberg, Susie Li, Anup Majumdar, Nancy Agrawal

J Clin Pharmacol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis